07 August 2000 00:00 [Source: ICB]
An overwhelming majorityof Glaxo Wellcome and SmithKline Beecham's shareholders have approved their merger to form GlaxoSmithKline.
More than 99% of GlaxoWellcome (GW) and SmithKline Beecham (SB) shareholders voted in favour of the merger.
Shareholders also approved option plans for Jean-Paul Garnier, the chief executive officer-designate of GlaxoSmithKline, as well as plans for the company's middle management.
GW took a £9m ($13.5m) charge in the second quarter to cover initial costs of the merger, and has put aside a further £11m for future integration. SB took a similar charge of £13m in the first half of this year and has put aside £15m for restructuring its manufacturing.
The merger, which is scheduled for 25 September, still requires anti-trust clearance in the US and approval by the UK high court.
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
Sample issue >>
My Account/Renew >>
Register for online access >>
|ICIS Top 100 Chemical Companies|
|Download the listing here >>|